Market Access of Biosimilars in the EU - Value Assessment/HTA?
-
With experts from HAS, NICE, RADS Denmark, G-BA, CatSalut Value assessment for biosimilars and the regulation of the substitution - these hot topics will be discussed at the meeting.52.5063153 13.3443265
- MAHP Newsletter
| Was |
|
|---|---|
| Wann |
14.12.2015 von 18:00 bis 20:30 |
| Veranstaltungsort | Pullman Berlin Schweizerhof |
| Stadt | Berlin |
| Kontaktname | Dr. Henriette Wolf-Klein |
| Kontakttelefon | +49 6221 500-680 |
| Zielgruppe |
This meeting addresses the needs of managing directors and co-workers in the pharmaceutical industry who are involved in market access and healthcare management of biosimilars. Especially those who are responsible for the international business will benefit from this meeting. |
| Termin übernehmen |
vCal
iCal
|
Aims and objectives:
Biosimilars are playing an increasingly important role in the national healthcare systems of the EU. But market access and reimbursement are facing challenges:
- Is there a consensus regarding whether or not HTA assessment is necessary for biosimilars?
- How can a substitution be regulated and potentially also be enforced?
These and further topics will be addressed in an intensive discussion among experts from five national HTA bodies.
Topics:
- Market access for biosimilars in Germany - the current challenges and regulatory trends at a glance
- Market access for biosimilars in the UK, France, Germany, Spain/Catalonia and Denmark
- Current discussion: Value assessment for biosimilars foreseen? Substitution regulated?
Weitere Informationen über diesen Termin…
FORUM Institut für Management GmbH
Programm
1512238_Klappkarte.pdf
—
PDF document,
223 kB (229,075 bytes)
